Global Healthcare Innovation Roadshow Investor Call: Projects from Canada, UK, Belgium, and Singapore Announced
The Top 100 Future Healthcare Conference has consistently prioritized the cultivation of venture capital relationships as one of its core principles. In April 2021, VCBeat VB100 hosted a global roadshow for innovative healthcare projects on the shores of Taihu Lake in Suzhou. This year, VCBeat, in collaboration withEmbassy of Canada in China, UK Department for International Trade, Flanders Investment & Trade Office of the Consulate General of Belgium in Shanghai, New* Research Enterprise Cooperation CenterCo-host global roadshows for innovative healthcare projects, featuring dedicated sessions for each country. Building on the continued connection between venture capital and startups, and empowering healthcare enterprises to engage with leading investment institutions, this initiative aims to enrich the international healthcare venture capital ecosystem.
VCBeat is currently inviting investors to serve as interactive commentary guests for its international roadshow recordings. Below are the project details for each session; all interested investors are welcome to register.Sign up now to receive a complimentary "Le Xiang All-Access Pass" (valued at RMB 269) for the 2022 6th Future Healthcare Top 100 Online Cloud Summit, including 20 networking privileges.
One
Project/Company Name:
CAE Healthcare
Project Overview
CAE Healthcare is dedicated to improving clinical education and patient safety through simulation-based training solutions. With a mission to enhance clinical competence and performance, we develop evidence-based curricula and innovative learning technologies for healthcare education.
CAE Medicor - Realistic, durable, easy-to-use task trainers that allow the practice of essential clinical skills virtually or in the classroom.
CAE Aria supports healthcare education for pediatric patients and advanced training requirements for PALS, PEARS and APLS certifications.
Target Financing Round:
N/A
Target Financing Amount for This Round:
None available
Use of Proceeds:
None
—
Two
Project/Company Name:
PMT MRI-Guided Real-Time Puncture Robot
Project Overview
Jingzhun Yixie is an international medical device startup specializing in intelligent surgical robotics, with technology and products at the forefront of global innovation. The company has received direct investment from a central state-owned enterprise. In close collaboration with prestigious research institutions such as Tsinghua University, and guided by Academician Dong Jiahong’s philosophy of “Precision Surgery,” Jingzhun Yixie is committed to its mission of “advancing medical technology to serve more patients.” It provides precise, safe, and user-friendly surgical solutions based on intelligent surgical robots, empowering physicians to deliver better patient care and making significant contributions to tackling major diseases such as liver cancer. The company brings together top-tier talent from industry, academia, research, and clinical practice. Its technical team includes multiple world-class experts with over 20 years of experience in robotics R&D. The medical advisory board comprises leading clinical specialists, particularly renowned in the fields of liver cancer and interventional therapy. The operations team consists of seasoned international management professionals with extensive expertise in product management, engineering commercialization, and market development. Furthermore, the company has established a comprehensive quality management system for medical device products to meet regulatory certification requirements.
Target Funding Round:
Pre-Series A
Target Round Financing Amount:
30 million
Use of Proceeds:
Deepening R&D and Manufacturing
—
Three
Project/Company Name:
Ocular Muscle and Nerve Stimulator
Project Overview
The ocular neuromuscular stimulator is the world’s first and only medical device designed for the treatment of congenital nystagmus. Congenital nystagmus is a genetic disorder that typically manifests between three and six months of age and persists throughout the patient’s life. It is characterized by involuntary, continuous, horizontal oscillatory eye movements, which cause significant visual impairment and severely compromise the patient’s quality of life. Often referred to as the “cancer” of ophthalmology, congenital nystagmus remains a formidable global medical challenge.
Chao Mu Technology has translated the technological achievements of Professor Wang Lejin from the Department of Ophthalmology at Peking University People's Hospital into a practical application, developing an ocular neuromuscular stimulator. Professor Wang is a leading expert in the treatment of nystagmus, both in China and globally. Drawing on years of clinical experience, he has creatively pioneered a novel electrophysiological approach to treating nystagmus. Compared with traditional surgical interventions, this new method preserves the patient’s neuromuscular integrity, offers stable therapeutic outcomes, and demonstrates favorable long-term prognosis. Based on this therapy, a neuromuscular stimulator designed for human implantation has been developed to significantly alleviate, and potentially cure, congenital nystagmus. The electrical stimulator for nystagmus integrates multidisciplinary expertise in medicine, biomaterials, and integrated circuit technology, providing an innovative solution to a challenging ophthalmic condition that has long plagued patients worldwide. The product is currently in the prototype development stage, has successfully completed eight human trials, and has obtained a global PCT invention patent.
Target Financing Round:
Series A+
Target Round Financing Amount:
50 million
Use of Funds:
R&D of Medical Integrated Chips and New Product Development
—
Four
Project/Company Name:
Nuelos AI – Revolutionary Non-Contact Health Monitoring Technology
Project Overview
Headquartered in Toronto, Canada, NuraLogix Corporation is a company specializing in the development and application of artificial intelligence technologies in the digital health sector. Building on years of research in neuroscience, psychology, and machine learning, the company has invented Transdermal Optical Imaging™ (TOI™) technology, which enables remote, non-contact, real-time, and continuous measurement of key physiological and psychological indicators—such as heart rate, respiration, blood pressure, psychological stress, and emotions—using standard cameras.
Nuros focuses on the digital health sector, with broad application prospects in telemedicine, health insurance, elderly care, Employee Assistance Programs (EAP), automotive electronics, consumer goods, and public health. It has been adopted by numerous world-renowned enterprises to provide various health services to their customers.
Target Funding Round:
Series B+
Target Round Funding Amount:
$10 million
Use of Funds:
Global Market Promotion and Sales
—
Five
Project/Company Name:
Qidni
Project Overview
Qidni is a startup developing artificial kidneys using novel nanomaterials. The company has conducted multiple animal studies and is preparing to advance to clinical trials.
Target Financing Round:
Series A
Target Funding Amount for This Round:
2M
Use of Funds:
Clinical Trials
—
Six
Project/Company Name:
Cyclica
Project Overview
Cyclica is an AI-powered platform that assists pharmaceutical companies in research and development, and has established partnerships with numerous leading pharmaceutical firms.
Target Funding Round:
Series C
Target Round Funding Amount:
30M
Use of Proceeds:
Intelligent Platform R&D
—
Welcome Investors to Register (Registration QR Code)
As some project presenters will deliver their pitches in English, we request that the judging panelists be able to communicate fluently in English with the project teams.
One
Project/Company Name:
Congenica - An AI-Driven Platform for Genetic Disease Research and Diagnosis Based on Large-Scale Genomic Projects
Project Overview
Congenica is a digital health company headquartered in Cambridge, UK. Spun out of the Wellcome Sanger Institute in 2014, it was founded by Professor Richard Durbin, a world-leading bioinformatics expert; Professor Matt Hurles, a human geneticist; and two clinicians from Great Ormond Street Hospital for Children in the UK. The company provides an AI-driven platform for research and diagnosis of genetic diseases based on large-scale genomic projects.
After eight years of development, Congenica has become one of the most renowned global providers of platforms for genetic disease research and diagnostics based on large-scale genomics initiatives. Its analysis software is the only whole-genome analysis solution adopted by a national healthcare reimbursement system. Congenica is a partner in major genomics projects such as the UK’s 100,000 Genomes Project and the Hong Kong Genome Project. The company’s products have obtained CE-IVD certification in the UK and the European Union and are currently undergoing FDA review in the United States. In 2021, Congenica’s artificial intelligence algorithms, developed based on extensive experience with large-scale genomics, received the Horizon Award from MIT SOLVE, an initiative under the Massachusetts Institute of Technology (MIT).
As a global leader in digital health, Congenica is also expanding its applications across multiple fields, including oncology and pharmacogenomics. With operations extended to more than 25 countries worldwide, the company leverages advanced artificial intelligence integrated with large-scale genomic project data to serve human health.
Target Funding Round:
Not Disclosed
Target Round Financing Amount:
Not disclosed at this time
Use of Proceeds:
Not disclosed at this time
—
Two
Project/Company Name:
"OXSIGHT Intelligent Bionic Glasses" from Oxford, UK
Project Overview
OXSIGHT, originating from the University of Oxford in the United Kingdom, is a premier wearable artificial intelligence vision company globally known for seamlessly integrating three key technologies—machine learning and deep learning, wearable technology, and machine vision—and successfully commercializing its products. Deep learning algorithms based on mobile technology represent one of the core technologies underpinning its current product offerings. This technology stems from a fundamental vision science research project commissioned by the UK Department of Health in 2010 and led by the University of Oxford, which investigated how the brain interprets visual information. Consequently, OXSIGHT has also conducted extensive in-depth research in the fields of neurology and brain science.
Intelligent Bionic Glasses, a new product category pioneered globally by OXSIGHT, are a “cutting-edge” device developed based on wearable AI vision technology for individuals with low vision (visual impairment). They help patients with low vision suffering from “visual field loss” due to conditions such as “macular degeneration” and “glaucoma” to “see the world again.”
Target Financing Round:
UK Headquarters - Pre-B, China Joint Venture - Angel Round
Target Funding Amount for This Round:
RMB 50 million (or GBP 5 million)
Use of Funds:
This round of capital investment will be primarily allocated to order production, delivery, and the global expansion of business operations.
—
Three
Project/Company Name:
LIT: Real-Time Immunoassay Technology for Sepsis
Project Overview
Seroxo, a UK-based rapid diagnostics company, provides real-time immunoassay testing via its LITTM platform to 50 million sepsis patients worldwide. The device has secured patents in the United States, Europe, and China, and is currently pursuing FDA and UKCA certifications. By integrating with a digital app and cloud-based platform, the LITTM device enables healthcare professionals to achieve over 99% accuracy in sepsis diagnosis and prognosis within 10 minutes using only a small drop of capillary blood from a finger prick, while also facilitating data tracking and sharing. Its portable design and robust technical support allow for rapid, real-time patient testing in ambulances, emergency departments, inpatient wards, and intensive care units. In contrast, existing sepsis tests typically require 6–24 hours, often leading to severe delays in treatment. LITTM addresses the critical need for rapid diagnostics in the time-sensitive management of sepsis.
Target Financing Round:
Series A Financing
Target Round Financing Amount:
$9 million
Use of Proceeds:
Engage a Contract Research Organization (CRO) to secure product marketing authorization from the UK and US regulatory authorities.
—
Four
Project/Company Name:
Non-Invasive Cardiac Diagnostic Device—Magnetocardiograph
Project Overview
Magnetocardiography (MCG) instruments are used to measure and analyze the magnetic fields generated by cardiac electrical currents. Ionic activity across myocardial cell membranes creates potential differences on the body surface, which can be recorded by an electrocardiogram (ECG). Concurrently, this electrical activity produces corresponding changes in the magnetic field. Magnetocardiography (MCG) is the technique and method for recording these time-dependent variations in the electromagnetic field (i.e., magnetic field strength or magnetic flux density) generated by the heart. In comparison, MCG instruments are highly sensitive to tangential and vortex current signals that are poorly detected by ECGs. Since the electromagnetic signals produced by the heart are not influenced by surrounding organs, MCG can accurately reflect the true electrophysiological status of specific cardiac regions. An MCG instrument can be conceptualized as an aggregate of countless internal ECG recorders. MCG is non-invasive and involves no energy radiation during diagnosis; for example, it does not require X-rays, ultrasound, or magnetic resonance imaging (MRI). It only requires measurement of the physiological magnetic field above the thoracic cavity. Therefore, the examination is entirely risk-free and can be repeated as frequently as needed. Currently, in clinical practice, MCG is used for the early diagnosis of acute and chronic myocardial ischemia, detection of viable myocardium within infarcted areas after myocardial infarction, assessment of the risk of malignant arrhythmias, and follow-up of treatment for coronary heart disease patients (including pharmacological therapy, coronary stenting, and coronary artery bypass grafting).
Target Funding Round:
angel round investment
Target Round Financing Amount:
3000w
Use of Proceeds:
For r&d and marketing
—
Five
Project/Company Name:
MediSieve Limited
Project Overview
Magnetic blood filtration: platform therapy and drug-delivery
Target Financing Round:
Series A
Target Round Financing Amount:
€10m
Use of Proceeds:
Pivotal clinical studies and initial regulatory approval
—
Six
Project/Company Name:
Kmira
Project Overview
Kmira is a tech start-up focused in advancing global communication – our aim is to improve communication globally using the latest in technology. In the Health industry we would like to see more globalisation of services.
Our research shows that most health services restricted to the country of origin, we would like to change this by allowing health works to operate more globally. We would like to bring health services to those that can’t access it at the moment and also to help upskill heath works around the world through our training programmes. Via this event we are keen to develop relationships with hospitals and health workers around the world but also possible investors who share our vision.
Target Financing Round:
Seed
Target Round Funding Amount:
$2,000,000 USD
Use of Proceeds:
Tech Development
—
We welcome investors to register (registration QR code)
As some project presenters will deliver their pitches in English, it is requested that the judging panel members be able to communicate fluently in English with the project teams.
One
Project/Company Name:
Elmedix
Project Overview
ElmediX is a climical stage oncology company, founded in 2015 as a spin-off of the University of Antwerp to develop a disruptive solution for (pancreatic) cancer and other life-threatening diseases. Their technology is a whole body thermal therapy which increases survival, improves response rates to treatment and raises quality of life of pancreatic cancer patients. ElmediX has developed a safe and reliable technology platform that accurately administers the optimal thermal dose to boost conventional treatments.
Target Financing Round:
A-Series
Target Financing Amount for This Round:
20Million USD
Use of Proceeds:
clinical development to Phase III, and FDA and CE approval
—
Two
Project/Company Name:
Fertiga
Project Overview
Founded in 2017, Fertiga is adiagnostic company and spin-off from the VUB (University Brussels). The company is a first-in-Class Diagnostics for female assisted reproduction technologies
(IVF-ICSI), and developed the Aurora Test for IVF-ICSI which significantly increases pregnancy success from 29% to 61%
The test is clinically validated in 2 studies in 757 patients (published)
and is non-invasive to the embryo, and avoids multiple births
Target Financing Round:
Series A
Target Financing Amount for This Round:
20 Million USD
Use of Proceeds:
Clinical development & Commercialization in China & German
—
Three
Project/Company Name:
Etherna
Project Overview
Etherna is a clinical stage mRNA company with a Joint Venture with Grand Pharma in Nanjing. The company has been set up in 2016 and develops 2nd generation mRNA therapies in oncology and infectious diseases. It has 4 innovative mRNA platformd with First-in-Class and Best-in-Class potential and own mRNA-LNPprocess technologies & formulations
Target Funding Round:
C-Series / cross-over round for IPO
Target Round Funding Amount:
80Million USD
Use of Proceeds:
develop pipeline to bring more assets in clinical stage.
—
Welcome Investors to Register (Registration QR Code)
As some project presenters will deliver their pitches in English, it is requested that the commenting guests be able to communicate fluently in English with the project teams.
One
Project/Company Name:
Development of the "Technology Middle Platform" for Intelligent Surgical Robots
Project Overview
As the world’s first smart healthcare product pioneered by Zhongyi Zhichuang, “Aimusi MCP1” integrates cutting-edge smart healthcare technologies into a core platform—the Technical Middle Platform. Leveraging the comprehensive empowerment of Aimusi’s intelligent backend (including cloud computing, artificial intelligence, information integration, process optimization, etc.), the Technical Middle Platform establishes a complete ecosystem for modern smart healthcare. It consolidates individual smart healthcare products into a comprehensive system of smart healthcare products and services, leading the medical and broader health industries into the era of intelligence.
By leveraging the advanced technologies embedded in the Aims MCP1 technical middle platform—including biomedical recognition, 3D organ reconstruction, augmented and virtual reality (AR/VR), AI-assisted diagnosis, intelligent surgical planning, intelligent surgical execution, integrated automatic control, integrated intelligent operation, and digital IoT—the time and cost required for developing smart medical devices can be significantly reduced, thereby lessening the reliance on multidisciplinary technologies in the development of intelligent medical products. This creates a cohesive smart medical product development platform that bridges traditional medical product upgrades, medical technology R&D, and medical product innovation. It effectively accelerates the industrialization of smart medical products, revitalizes the industry ecosystem, improves public health outcomes, and benefits hundreds of millions of people.
Target Financing Round:
Series A
Target Round Financing Amount:
RMB 20 million
Use of Funds:
Finalize product design and freeze specifications; establish a production line with an annual capacity of 400 units; produce and sell 20 units.
—
Two
Project/Company Name:
AI-Driven Precision Medicine Diagnostics: Digital Histopathology Biomarker Solutions
Project Overview
BioTotem specializes in applying artificial intelligence to biomedical image analysis, providing comprehensive solutions for clinicians, pharmaceutical companies, and researchers to address various complex and time-consuming biomedical image analysis tasks.
BioTotem’s solutions address diverse needs, including automated pharmacodynamic evaluation in preclinical animal models, fully quantitative interpretation of clinical endpoints, stratified screening of patients for clinical trial enrollment, and the establishment of digital companion diagnostic biomarkers. These capabilities help partners shorten drug development cycles and improve the success rate of regulatory approvals. Our product portfolio includes intelligent scoring systems for NASH, breast tumor-infiltrating lymphocytes (TILs), and tumor immunity.
Leveraging extensive expertise in medical image processing, artificial intelligence applications, data mining, and collaborations with the pharmaceutical industry, BioTotem, as a next-generation intelligent image analysis CRO, is committed to providing advanced imaging solutions to pharmaceutical companies and CROs.
Target Financing Round:
Pre-A
Target Round Financing Amount:
RMB 10 million
Use of Funds:
Team Expansion, Clinical Registration and Certification
—
Three
Project/Company Name:
Achieving Early Cancer Detection with Comprehensive Liquid Biopsy
Project Overview
Lusheng is a precision medicine company dedicated to the development and application of liquid biopsy technologies for early cancer screening and treatment selection in advanced-stage disease. Headquartered in Singapore and Palo Alto, USA, the company maintains subsidiaries in Suzhou and Hong Kong. Lusheng provides molecular testing services globally through laboratories accredited by CAP and CLIA.
Target Funding Round:
Series B
Target Funding Amount for This Round:
$50 million
Use of Funds:
Facility Construction, R&D Equipment Procurement, Clinical Trial Investment
—
Welcome Investors to Register (Registration QR Code)
Since some project presenters will deliver their pitches in English, we request that the judging panelists be able to communicate fluently in English with the project teams.
